Hope S. Rugo, MD

Articles

Dr. Rugo on 20-Year Span of Breast Cancer Advancements

March 10th 2019

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Comprehensive Cancer Center, discusses the therapeutic advancements in the breast cancer space in the past 20 years.

Dr. Rugo on Hormone Therapy for Patients With Breast Cancer

November 7th 2017

Hope S. Rugo MD, professor of medicine and director of breast oncology and clinical trials education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses hormone therapy for patients with breast cancer.

Dr. Rugo on the Future of Extended Adjuvant Hormone Therapy for Breast Cancer

August 29th 2017

Hope S. Rugo, MD, a professor of medicine and director of the Breast Oncology Clinical Trials Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco discusses the future of extended adjuvant hormone therapy for patients with breast cancer.

Dr. Rugo on Extended Adjuvant Hormone Therapy for Breast Cancer

July 17th 2017

Hope S. Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant hormone therapy for patients with breast cancer.

Dr. Rugo on the Significance of the MONARCH I Trial for Breast Cancer

June 2nd 2017

Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the significance of the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

Dr. Rugo Discusses MONARCH I in HR+ HER2- Breast Cancer

April 7th 2017

Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

Dr. Rugo on SWISH Trial for HR-Positive Breast Cancer

July 18th 2016

Hope S. Rugo, MD, professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Hellen Diller Family Comprehensive Cancer Center, discusses the results of the SWISH trial, which examined a dexamethasone-based mouthwash for the prevention of everolimus/exemestane stomatitis in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.

Dr. Rugo Discusses How Stomatitis Impacts the Efficacy of Everolimus

October 7th 2014

Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses a meta-analysis that examined how stomatitis impacts the efficacy of everolimus

Dr. Rugo on Metastatic Breast Cancer Guidelines

October 11th 2013

Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses new guidelines for the treatment of patients with metastatic breast cancer.

Dr. Rugo on PI3K and mTOR Inhibitors for Breast Cancer

August 8th 2013

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, gives an overview of the development of PI3K and mTOR inhibitors for the treatment of breast cancer.

Dr. Rugo on Chemotherapy for Metastatic Breast Cancer

May 28th 2013

Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with metastatic breast cancer with chemotherapy.

Dr. Rugo on the Standard for Front-Line Chemotherapy

March 8th 2013

Hope S. Rugo, MD, at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the standard for front-line chemotherapy in patients with breast cancer.

Dr. Hope Rugo Previews the 2012 SABCS Program

November 13th 2012

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, previews the 2012 San Antonio Breast Cancer Symposium program.

Dr. Rugo on Antiangiogenic Therapies in Breast Cancer

August 28th 2012

Dr. Hope Rugo, from the UCSF Helen Diller Family Comprehensive Cancer Center, Examines Angiogenesis Inhibition Trials in Advanced Breast Cancer.

Dr. Rugo on Paclitaxel Superiority in Advanced Breast Cancer

June 5th 2012

Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.

Dr. Rugo on the Efficacy of Bevacizumab in Breast Cancer

October 17th 2011

Dr. Hope S. Rugo from the University of California, San Francisco on the Efficacy of Bevacizumab in Breast Cancer

Dr. Rugo on Proliferation as an Anti-Angiogenesis Marker

October 5th 2011

Dr. Hope S. Rugo from University of California, San Francisco on Proliferation as an Anti-Angiogenesis Marker

Dr. Rugo on VEGF-A as an Avastin Response Predictor

September 16th 2011

Dr. Hope Rugo from UCSF Cancer Center on VEGF-A as an Avastin Response Predictor

Dr. Rugo on the Future of Angiogenesis in Breast Cancer

September 9th 2011

Dr. Hope S. Rugo from UCSF Cancer Center on the Future of Angiogenesis in Breast Cancer

Dr. Rugo on Anti-Angiogenesis Therapy Response Predictors

September 7th 2011

Dr. Hope S. Rugo from University of California, San Francisco on Anti-Angiogenesis Therapy Response Predictors